| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Across the last three months, Gilead Sciences, Inc.'s insiders have reduced their positions by a net 15,000 shares worth roughly $2.0M.
GILD sits in the Biotechnology industry within the Health Care sector, so this activity is best read against the sector's broader insider trend.
| Role | Insider | Shares | Value | 30d |
|---|---|---|---|---|
| CEO | 92.1K | $12.74M | - | |
| Other | 46.6K | $6.45M | - | |
| Other | 27.9K | $3.85M | - | |
| CFO | 27.9K | $3.85M | - | |
| VP | 20.0K | $2.77M | - |
Buys and sells only
| Date | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|
| Jul 2, 2018 | Martin John C | Director | Sale+OE | 50,000 | $70.81 | $3,540,282.31 | -0.8% | |
| Jun 1, 2018 | Martin John C | Director | Sale+OE | 50,000 | $68.13 | $3,406,495.00 | -1.6% | |
| May 4, 2018 | Cogan John Francis | Director | Sale+OE | 5,836 | $65.09 | $379,885.08 | -10.0% | |
| May 1, 2018 | Martin John C | Director | Sale+OE | 50,000 | $72.19 | $3,609,660.00 | -1.6% | |
| Apr 27, 2018 | Cogan John Francis | Director | Sale+OE | 5,833 | $73.91 | $431,117.03 | -10.0% | |
| Apr 20, 2018 | Cogan John Francis | Director | Sale+OE | 5,833 | $73.74 | $430,130.11 | -5.0% | |
| Apr 13, 2018 | Cogan John Francis | Director | Sale+OE | 5,833 | $75.56 | $440,741.48 | -10.0% | |
| Apr 6, 2018 | Cogan John Francis | Director | Sale+OE | 5,833 | $74.47 | $434,383.51 | -10.0% | |
| Apr 2, 2018 | Martin John C | Director | Sale+OE | 50,000 | $73.14 | $3,656,805.61 | -0.4% | |
| Apr 2, 2018 | Cogan John Francis | Director | Sale+OE | 5,833 | $74.93 | $437,066.69 | -10.0% |